A total of 119 patients with ES-SCLC were assessed, 49 in the pre-IVES interval and 70 in the IVES interval. The median age was 68 (IQR, 62-74) years, 48% (n = 57) were male, 33% (n = 39) had CNS ...
The role of platinum doublet as the chemotherapy backbone for first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) has been well established for decades. Immunotherapy has been ...
Background and Aim: Systemic treatments of advanced hepatocellular carcinoma (AHCC) have offered marginal clinical benefits. Recently, Italian investigators reported that etoposide and epirubicin ...
A shortage of essential intravenous (IV) etoposide lasted from 2018 until 2020 in Ontario, Canada, allowing for a natural experiment in which external factors (IV etoposide availability) dictated ...
In 1987, the CALGB published a seminal report (CALGB 8083) describing the benefits of thoracic irradiation when given concurrently with chemotherapy for patients with LS-SCLC. [14] Improvements in ...
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer that accounts for ~15% of all lung cancer cases. Despite being initially responsive to treatment, the vast majority of tumors ...
Combining immunotherapy with chemotherapy may improve survival in extensive-stage small cell lung cancer without increasing treatment-related toxicity. The study showed a median overall survival of 14 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results